We have located links that may give you full text access.
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
Hepatology : Official Journal of the American Association for the Study of Liver Diseases 2024 March 7
BACKGROUND AIMS: The landscape in primary biliary cholangitis (PBC) has changed with the advent of second-line treatments. However, the use of obeticholic acid (OCA) and fibrates in PBC-related cirrhosis is challenging. We assessed the impact of receiving a second-line therapy as a risk factor for decompensated cirrhosis in a real-world cirrhotic PBC population, and identify the predictive factors for decompensated cirrhosis in these patients.
APPROACH RESULTS: Multicenter study enrolling 388 PBC-cirrhotic patients from the Spanish ColHai registry. Biopsy (20%), ultrasound (59%), or transient elastography (21%) defined cirrhosis, and the presence of varices and splenomegaly defined clinically significant portal hypertension (CSPH). Paris-II and POISE criteria determined the response to ursodeoxycholic acid (UDCA), fibrates (n=93), and OCA (n=104). The incidence of decompensated cirrhosis decreased for UDCA versus OCA or fibrates in the real-world population, but they were similar considering the PS-matched cohort (UDCA 3.77 vs. second-line therapy 4.5 100 persons-year, respectively), as patients on second-line therapy exhibited advanced liver disease. Consequently, GGT, albumin, platelets, CSPH, and UDCA response were associated with a decompensating event. OCA response (achieved in 52% of patients) was associated with bilirubin [OR 0.21 (95%CI 0.06-0.73)] and AST [OR 0.97 (95%CI 0.95-0.99)], while fibrate response (achieved in 55% of patients) with AST [OR 0.96 (95%CI 0.95-0.98)]. In OCA-treated patients, drug response [sHR 0.23 (95%CI 0.08-0.64)], diabetes [sHR 5.62 (95%CI 2.02-15.68)], albumin [sHR 0.34 (95%CI 0.13-0.89)], and platelets [sHR 0.99 (95%CI 0.98-1.00)] were related to decompensation. In fibrate-treated patients, drug response [sHR 0.36 (95%CI 0.14-0.95)], albumin [sHR 0.36 (95%CI 0.16-0.81)], and CSPH [sHR 3.70 (95%CI 1.17-11.70)] were associated with decompensated cirrhosis.
CONCLUSIONS: Advanced PBC, rather than OCA and fibrates, was found to be associated with decompensating events. Therefore, biochemical and clinical variables should be considered when making decisions about the management of these drugs. Moreover, a positive response to OCA and fibrates reduced the risk of decompensation.
APPROACH RESULTS: Multicenter study enrolling 388 PBC-cirrhotic patients from the Spanish ColHai registry. Biopsy (20%), ultrasound (59%), or transient elastography (21%) defined cirrhosis, and the presence of varices and splenomegaly defined clinically significant portal hypertension (CSPH). Paris-II and POISE criteria determined the response to ursodeoxycholic acid (UDCA), fibrates (n=93), and OCA (n=104). The incidence of decompensated cirrhosis decreased for UDCA versus OCA or fibrates in the real-world population, but they were similar considering the PS-matched cohort (UDCA 3.77 vs. second-line therapy 4.5 100 persons-year, respectively), as patients on second-line therapy exhibited advanced liver disease. Consequently, GGT, albumin, platelets, CSPH, and UDCA response were associated with a decompensating event. OCA response (achieved in 52% of patients) was associated with bilirubin [OR 0.21 (95%CI 0.06-0.73)] and AST [OR 0.97 (95%CI 0.95-0.99)], while fibrate response (achieved in 55% of patients) with AST [OR 0.96 (95%CI 0.95-0.98)]. In OCA-treated patients, drug response [sHR 0.23 (95%CI 0.08-0.64)], diabetes [sHR 5.62 (95%CI 2.02-15.68)], albumin [sHR 0.34 (95%CI 0.13-0.89)], and platelets [sHR 0.99 (95%CI 0.98-1.00)] were related to decompensation. In fibrate-treated patients, drug response [sHR 0.36 (95%CI 0.14-0.95)], albumin [sHR 0.36 (95%CI 0.16-0.81)], and CSPH [sHR 3.70 (95%CI 1.17-11.70)] were associated with decompensated cirrhosis.
CONCLUSIONS: Advanced PBC, rather than OCA and fibrates, was found to be associated with decompensating events. Therefore, biochemical and clinical variables should be considered when making decisions about the management of these drugs. Moreover, a positive response to OCA and fibrates reduced the risk of decompensation.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app